title: Pregabalin reduces acute inflammatory and persistent pain associated with nerve injury and cancer in rat models of orofacial pain.
abstract: OBJECTIVE
  To assess the analgesic effect of pregabalin in orofacial models of acute inflammatory pain and of persistent pain associated with nerve injury and cancer, and so determine its effectiveness in controlling orofacial pains having different underlying mechanisms.
  
  
  METHODS
  Orofacial capsaicin and formalin tests were employed in male Wistar rats to assess the influence of pregabalin (or vehicle) pretreatment in acute pain models, and the results from these experiments were analyzed by one-way analysis of variance (ANOVA) followed by Newman Keuls post-hoc test. Pregabalin (or vehicle) treatment was also tested on the facial heat hyperalgesia that was evaluated in rats receiving injection of the inflammatory irritant carrageenan into the upper lip, as well as after constriction of the infraorbital nerve (a model of trigeminal neuropathic pain), or after inoculation of tumor cells into the facial vibrissal pad; two-way repeated measures ANOVA followed by Newman-Keuls post-hoc test was used to analyze data from these experiments.
  
  
  RESULTS
  Facial grooming induced by capsaicin was abolished by pretreatment with pregabalin at 10 and 30 mg/kg. However, pregabalin failed to modify the first phase of the formalin response, but reduced the second phase at both doses (10 and 30 mg/kg). In addition, treatment of rats with pregabalin reduced the heat hyperalgesia induced by carrageenan, as well as by nerve injury and facial cancer.
  
  
  CONCLUSIONS
  Pregabalin produced a marked antinociceptive effect in rat models of facial inflammatory pain as well as in facial neuropathic and cancer pain models, suggesting that it may represent an important agent for the clinical control of orofacial pain.
authors.forename: Wagner
authors.initials: W
authors.lastname: Hummig
authors.forename: Caroline Machado
authors.initials: CM
authors.lastname: Kopruszinski
authors.forename: Juliana Geremias
authors.initials: JG
authors.lastname: Chichorro
mesh_terms: D059787:Acute Pain / Q000517:prevention & control; D000700:Analgesics / Q000627:therapeutic use*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002211:Capsaicin / Q000009:adverse effects; D002351:Carrageenan / Q000009:adverse effects; D059350:Chronic Pain / Q000517:prevention & control; D004195:Disease Models, Animal; D005153:Facial Neoplasms / Q000150:complications; D005157:Facial Pain / Q000517:prevention & control*; D006358:Hot Temperature / Q000009:adverse effects; D006930:Hyperalgesia / Q000209:etiology / Q000517:prevention & control; D007509:Irritants / Q000009:adverse effects; D008047:Lip Diseases / Q000209:etiology; D008297:Male; D009368:Neoplasm Transplantation; D009915:Orbit / Q000294:innervation; D010147:Pain Measurement; D000069583:Pregabalin; D011897:Random Allocation; D017208:Rats, Wistar; D018689:Sensory System Agents / Q000009:adverse effects; D014277:Trigeminal Neuralgia / Q000139:chemically induced / Q000517:prevention & control; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000700:Analgesics; D000893:Anti-Inflammatory Agents; D007509:Irritants; D018689:Sensory System Agents; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; D002351:Carrageenan; D002211:Capsaicin